Logo Image
|Articles|August 13, 2012

FDA Approves Vaccine Formulation for the 2012-2013 Influenza Season

The Food and Drug Administration (FDA) announced today that it has approved the 2012-2013 influenza (flu) vaccine formulation for all six manufacturers licensed to produce and distribute the vaccines in the United States.
 
Each year experts from the FDA, the World Health Organization, the Centers for Disease Control and Prevention (CDC), and other public health experts study influenza virus samples and global disease patterns to identify virus strains likely to cause the most illness during the upcoming flu season.
 
Based on that information and the recommendations of the FDAs Vaccines and Related Biological Products Advisory Committee, the strains selected for inclusion in the 2012-2013 flu vaccines are:
- A/California/7/2009 (H1N1)-like virus
- A/Victoria/361/2011 (H3N2)-like virus
- B/Wisconsin/1/2010-like virus

 
While the H1N1 virus is the same as what was included in the 2011-2012 influenza vaccines, this years influenza H3N2 and B viruses differ from those in the 2011-2012 influenza vaccines.


Vaccination remains the cornerstone of preventing influenza, a contagious respiratory disease caused by different influenza viruses infecting the nose, throat and lungs. This years seasonal vaccines will provide protection against the three influenza virus strains that global surveillance indicates are likely to be the most common strains circulating during the upcoming season.
 
There is always a possibility of a less than optimal match between the virus strains predicted to circulate and the virus strains that end up causing the most illness. However, even if the vaccine and the circulating strains are not an exact match, the vaccine may reduce the severity of the illness or may help prevent influenza-related complications.
 
The best way to prevent influenza is by getting vaccinated each year, says Karen Midthun, MD, director of the FDAs Center for Biologics Evaluation and Research. It is especially important to get vaccinated this year because two of the three virus strains used in this seasons influenza vaccines differ from the strains included in last years vaccines.
 
According to the CDC, between 5 percent and 20 percent of the U.S. population develops influenza each year. This leads to more than 200,000 hospitalizations from related complications. Influenza seasons are unpredictable and can be severe, with annual influenza-related deaths ranging from a low of about 3,000 to a high of 49,000 people in the U.S. The CDCs Advisory Committee on Immunization Practices, recommends that everyone six months of age and older receive an annual influenza vaccine.
 
Health care providers play an important role in advising their patients to get vaccinated each year and should also protect themselves, their patients, their family, and the community from influenza by getting vaccinated. 
 
The manufacturers licensed to produce the nations 2012-2013 flu vaccines and the brand names of the vaccines for the upcoming flu season are:
- Afluria, manufactured by CSL Limited
- Fluarix, manufactured by GlaxoSmithKline Biologicals
- FluLaval, manufactured by ID Biomedical Corporation
- FluMist, manufactured by MedImmune Vaccines Inc.
- Fluvirin, manufactured by Novartis Vaccines and Diagnostics Limited
- Fluzone, Fluzone High-Dose and Fluzone Intradermal, manufactured by Sanofi Pasteur

Related to this article

View more
Infection preventionists in full PPE with children in DRC. (Image credit: author with AI)
Chasing the Bundibugyo Outbreak: How Static Numbers Hide a Moving Epidemic
Nearly 4 months into the DRC's Bundibugyo virus disease outbreak, some indicators suggest transmission may be slowing. But shifting hotspots, treatment-center capacity problems, community deaths, and incomplete surveillance data show why national case totals alone cannot determine whether containment has been achieved.
Read more
Health care workers from the US speaking with other health care workers in DRC. (Image credit: author with AI)
What Outbreak Metrics Can and Cannot Tell Us About the Ebola DRC Response
Is the Ebola outbreak in the DRC getting better? The answer depends on which numbers you examine. Several important indicators are moving in the right direction, including slower case growth and a declining Rₜ. But major gaps remain in contact tracing, testing, community deaths, safe burial coverage, and treatment capacity in some of the hardest-hit areas. ICT takes a deeper look at the latest outbreak data and why the numbers suggest cautious optimism, not victory.
Read more
Dyan Troxell, MSN, RN, director of clinical education at HandCraft Linen Services; J.J. Odom, MBA, CHESP, CMIP, T-CHEST, university director of buildings and grounds for UConn Health and chair-elect of the AHE Board; and Jenna Rivers, MPH, CPH, CIC, manager of infection prevention and control at Moffitt Cancer Center in Tampa, Florida.
At AHE Exchange26: Building Safer, Smarter Reusable Linen Programs
At AHE Exchange 2026, ICT spoke with experts representing commercial laundry services, EVS, and infection prevention about the systems behind a successful reusable linen program. They discuss linen quality, reject rates, unnecessary waste, frontline education, data, PAR levels, infection prevention oversight, and why strong relationships between health care facilities and their laundry providers matter.
Read more
A group of students raising their hands in class during a lecture (Adobe Stock 292282454 by Mediteraneo
Once a Teacher, Always a Teacher: Why Infection Prevention Is Education
How do you celebrate an infection that never happened? That's one of the unusual challenges infection preventionists share with teachers. Both can spend their careers changing outcomes they may never see. Both educate people who don't always want to listen. Both are second-guessed. Both face burnout. And both must somehow keep remembering why they started.
Read more